Find News

Filter articles

Applied Filters

Showing 731 to 740 of 919 results

Teva bids $40bn for Mylan

EU, Israel22-04-2015

Pharmaceutical company Teva has offered to buy fellow drug maker Mylan in a deal that could be worth $40 billion.

Canada’s Supreme Court throws out Sanofi compensation appeal


The Supreme Court of Canada has dismissed an appeal by French pharmaceutical company Sanofi in its patent dispute with Canadian generic drug maker Apotex.

Claris Lifesciences settles propofol patent litigation with Fresenius Kabi


Healthcare company Fresenius Kabi and India-based generic drug maker Claris Lifesciences have settled their patent dispute, ending pending litigation.

Mylan head dismisses Teva merger

Israel, US20-04-2015

Mylan’s executive chairman Robert Coury has issued a statement confirming that his company and Teva will not merge.

Schiff Hardin hires life sciences specialist


Law firm Schiff Hardin has added a life sciences specialist as a partner in its intellectual property group.

Teva sues five companies for alleged Copaxone infringement


Israeli pharmaceutical company Teva has, in one single filing, accused five generic drug makers of infringing a patent covering its blockbuster multiple sclerosis drug Copaxone.

Federal Circuit upholds AzaSite eye drop patents


The US Court of Appeals for the Federal Circuit has upheld the validity of four patents covering conjunctivitis treatment AzaSite.

MSD targets Apotex in Nasonex infringement action


Merck Sharp & Dohme has sued Apotex at the US District Court for the District of New Jersey for allegedly infringing a patent covering hay fever nasal spray Nasonex.

Forest files fifth patent lawsuit to protect Viibryd


Forest Labs, a subsidiary of Actavis, has sued InvaGen for allegedly infringing four patents covering depression drug Viibryd, in what is the fifth related lawsuit.

Federal Circuit revives Apotex blood pressure case


A US appeals court has overturned a district court's decision to deny Apotex's request for a declaratory judgment that its proposed generic blood pressure drug would not infringe a patent owned by pharmaceutical company Daiichi Sankyo.

Showing 731 to 740 of 919 results